One in four U.S. children suffers from allergic diseases, and more than 6% of children are diagnosed with asthma, according to the Centers for Disease Control and Prevention.

The Food and Drug Administration approved two gene therapy strategies for patients 12 years and older with severe sickle cell disease. While these therapies have had early therapeutic success, patients often face cost and logistical hurdles to accessing them.

Appropriate antibiotic use and vaccination can help drive down rates of these infections, and AAP resources can guide pediatricians.

A new AAP clinical report describes risk and protective factors, motives and sources of nonmedical prescription drug use among adolescents and young adults. It also outlines what pediatricians can do to prevent and reduce harms related to such use.

After extensive review, the Food and Drug Administration is proposing to remove oral phenylephrine from over-the-counter nasal decongestant products. Public comments about the proposed order will be accepted through May 7, 2025.

Supply chain issues, manufacturing difficulties and increased demand have contributed to supply issues with a variety of drugs, immunizations and medical devices.

Delta-8 THC is an intoxicating substance found in low amounts in cannabis plants and likely is produced by synthetic methods.

The guideline addresses how to minimize risks and alleviate disparate pain treatment.

The FDA recommends clinicians stop prescribing the treatment and patients talk to their doctor about starting a different treatment.

Pediatricians wrote just 6% of the dispensed naloxone prescriptions for adolescents despite a 991% increase during the study period.

The Food and Drug Administration organizes public workshops to analyze issues that confound the development and use of pediatric therapeutics and to discuss and advance potential solutions.

Patients taking GLP-1 RAs may be asked to hold the medication before surgery or have longer fasting times.

The FDA has approved neffy epinephrine nasal spray from ARS Pharmaceuticals.

The FDA has approved three new treatments for Duchenne muscular dystrophy within the last year.

The One Health initiative emphasizes the need for various disciplines and sectors to come together to promote human, animal and environmental health, recognizing that the health of children and adults is tied closely to the health of animals and our shared environment.

Cell and gene therapies, which can cost millions of dollars per treatment course, raise serious questions about drug access and equity.

Lentocilin (benzathine benzylpenicillin tetrahydrate) is a powder and diluent for suspension for injection and is available in a strength of 1.2 million units.

The AAP was named among best companies in Chicago area; four-day CardioPREP course coming July 18; free courses on infection prevention and prenatal opioid exposure available now.

While it typically takes six to 10 years for a drug approved for adults to receive pediatric labeling, remdesivir was approved for use in pediatric patients, including neonates, about three years after approval for use in adults and adolescents.

The policy offers evidence-based guidance to promote safe medication ordering, storage and administration.